{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:31:31Z","timestamp":1788237091595,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Japan Agency for Medical Research","award":["24ck0106978h0001"],"award-info":[{"award-number":["24ck0106978h0001"]}]},{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Topical steroids may help prevent capecitabine-induced hand-foot syndrome in patients with colorectal cancer, as inflammation is involved in anti-tumor agent-induced hand-foot syndrome development. We assessed the preventive efficacy of medium-class topical corticosteroids for capecitabine-induced hand-foot syndrome in patients receiving adjuvant chemotherapy for colorectal cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This open-label, single-arm, single-center phase II study included patients with colorectal cancer receiving adjuvant chemotherapy with capecitabine\u2009+\u2009oxaliplatin. Prophylactic topical hydrocortisone butyrate (0.1%) was applied to the palms and soles from day 1 of adjuvant chemotherapy. The primary endpoint was grade\u2009\u2265\u20092 hand-foot syndrome incidence within four cycles. Secondary endpoints were the time to onset and incidence of each hand-foot syndrome grade, dose reduction, schedule delay, hand-foot syndrome-induced discontinuation, and other adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty patients were enrolled; three were excluded. Among the 47 included (median age\u2009=\u200954.5\u00a0years), 100% had Eastern Cooperative Oncology Group performance status 0, 36.1% were male, and 95.7% had pathological stage III disease. Hand-foot syndrome induced dose reduction, schedule delay, and discontinuation were required in 0, 2, and 0 patients, respectively, with a median relative capecitabine dose intensity of 100% within four cycles. Grade\u2009\u2265\u20092 hand-foot syndrome incidence during the cycles was 6.4%. Time to onset of grades\u2009\u2265\u20091 and\u2009\u2265\u20092 was 63.5 and 105.5\u00a0days, respectively. One patient experienced grade 3 hand-foot syndrome on day 164. The most common grade\u2009\u2265\u20092 adverse events were peripheral sensory neuropathy and neutropenia. No topical hydrocortisone butyrate (0.1%)-induced adverse events occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Topical hydrocortisone butyrate (0.1%) may prevent capecitabine-induced hand-foot syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Trial registration number and date of registration: This clinical trial is registered in the Japan Registry of Clinical Trials (jRCT) as jRCTs031220002).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-025-02857-4","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T13:48:36Z","timestamp":1755179316000},"page":"2316-2324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A phase II study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in patients with colorectal cancer receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study)"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3473-8244","authenticated-orcid":false,"given":"Yohei","family":"Iimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieko","family":"Sasuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Ahiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Monma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sakuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Aikou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Shida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"2857_CR1","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","volume":"378","author":"A Grothey","year":"2018","unstructured":"Grothey A, Sobrero AF, Shields AF et al (2018) Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 378:1177\u20131188. https:\/\/doi.org\/10.1056\/NEJMoa1713709","journal-title":"N Engl J Med"},{"key":"2857_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2020.10.480","volume":"32","author":"K Yamazaki","year":"2021","unstructured":"Yamazaki K, Yamanaka T, Shiozawa M et al (2021) Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III achieve-2 trial. Ann Oncol 32:77\u201384. https:\/\/doi.org\/10.1016\/j.annonc.2020.10.480","journal-title":"Ann Oncol"},{"key":"2857_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S2468-1253(17)30297-2","volume":"3","author":"T Hamaguchi","year":"2018","unstructured":"Hamaguchi T, Shimada Y, Mizusawa J et al (2018) Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial. Lancet Gastroenterol Hepatol 3:47\u201356. https:\/\/doi.org\/10.1016\/S2468-1253(17)30297-2","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2857_CR4","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1177\/1060028015594451","volume":"49","author":"T Yokokawa","year":"2015","unstructured":"Yokokawa T, Kawakami K, Mae Y et al (2015) Risk factors exacerbating hand-foot skin reaction induced by capecitabine plus oxaliplatin with or without bevacizumab therapy. Ann Pharmacother 49:1120\u20131124. https:\/\/doi.org\/10.1177\/1060028015594451","journal-title":"Ann Pharmacother"},{"key":"2857_CR5","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1634\/theoncologist.2011-0033","volume":"16","author":"V Sibaud","year":"2011","unstructured":"Sibaud V, Dalenc F, Chevreau C et al (2011) HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 16:1469\u20131478. https:\/\/doi.org\/10.1634\/theoncologist.2011-0033","journal-title":"Oncologist"},{"key":"2857_CR6","unstructured":"Network NCC. NCCN guidelines"},{"key":"2857_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2147\/PPA.S80327","volume":"9","author":"K Kawakami","year":"2015","unstructured":"Kawakami K, Nakamoto E, Yokokawa T et al (2015) Patients\u2019 self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis. Patient Prefer Adher 9:561\u2013567. https:\/\/doi.org\/10.2147\/PPA.S80327","journal-title":"Patient Prefer Adher"},{"key":"2857_CR8","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.3390\/curroncol28050342","volume":"28","author":"S Lakkunarajah","year":"2021","unstructured":"Lakkunarajah S, Breadner DA, Zhang H et al (2021) (2021) The influence of adjuvant chemotherapy dose intensity on five-year outcomes in resected colon cancer: a single centre retrospective analysis. Curr Oncol 28:4031\u20134041. https:\/\/doi.org\/10.3390\/curroncol28050342","journal-title":"Curr Oncol"},{"key":"2857_CR9","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1610-0387.2010.07449.x","volume":"8","author":"A Degen","year":"2010","unstructured":"Degen A, Alter M, Schenck F et al (2010) The hand-foot-syndrome associated with medical tumor therapy\u2014classification and management. J Dtsch Dermatol Ges 8:652\u2013661. https:\/\/doi.org\/10.1111\/j.1610-0387.2010.07449.x","journal-title":"J Dtsch Dermatol Ges"},{"key":"2857_CR10","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.21037\/apm-21-61","volume":"10","author":"W Lu","year":"2021","unstructured":"Lu W, Huang Z, Chen S et al (2021) The effectiveness of EVOSKIN\u00aePalm and sole moisturizing cream in treating capecitabine-associated hand-foot syndrome: a randomized double-blind clinical trial. Ann Palliat Med 10:3009\u20133017. https:\/\/doi.org\/10.21037\/apm-21-61","journal-title":"Ann Palliat Med"},{"key":"2857_CR11","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1200\/JCO.2010.31.1431","volume":"28","author":"SL Wolf","year":"2010","unstructured":"Wolf SL, Qin R, Menon SP et al (2010) Placebo-controlled trial to determine the effectiveness of a urea\/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol 28:5182\u20135187. https:\/\/doi.org\/10.1200\/JCO.2010.31.1431","journal-title":"J Clin Oncol"},{"key":"2857_CR12","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00432-010-0958-9","volume":"137","author":"RX Zhang","year":"2011","unstructured":"Zhang RX, Wu XJ, Lu SX et al (2011) The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II\/III colorectal cancer: a phase II randomized prospective study. J Cancer Res Clin Oncol 137:953\u2013957. https:\/\/doi.org\/10.1007\/s00432-010-0958-9","journal-title":"J Cancer Res Clin Oncol"},{"key":"2857_CR13","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/annonc\/mdr400","volume":"23","author":"RX Zhang","year":"2012","unstructured":"Zhang RX, Wu XJ, Wan DS et al (2012) Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol 23:1348\u20131353. https:\/\/doi.org\/10.1093\/annonc\/mdr400","journal-title":"Ann Oncol"},{"key":"2857_CR14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/ced.12538","volume":"40","author":"SJ Jo","year":"2015","unstructured":"Jo SJ, Shin H, Jo S et al (2015) Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis. Clin Exp Dermatol 40:260\u2013270. https:\/\/doi.org\/10.1111\/ced.12538","journal-title":"Clin Exp Dermatol"},{"key":"2857_CR15","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3349\/ymj.2009.50.6.796","volume":"50","author":"HS Son","year":"2009","unstructured":"Son HS, Lee WY, Lee WS et al (2009) Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. Yonsei Med J 50:796\u2013802. https:\/\/doi.org\/10.3349\/ymj.2009.50.6.796","journal-title":"Yonsei Med J"},{"key":"2857_CR16","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","volume":"19","author":"E Van Cutsem","year":"2001","unstructured":"Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097\u20134106. https:\/\/doi.org\/10.1200\/JCO.2001.19.21.4097","journal-title":"J Clin Oncol"},{"key":"2857_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","volume":"17","author":"JL Blum","year":"1999","unstructured":"Blum JL, Jones SE, Buzdar AU et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485\u2013493. https:\/\/doi.org\/10.1200\/JCO.1999.17.2.485","journal-title":"J Clin Oncol"},{"key":"2857_CR18","first-page":"1161","volume":"18","author":"W Scheithauer","year":"2004","unstructured":"Scheithauer W, Blum J (2004) Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Williston Park) 18:1161\u20131168 (1173; discussion 1173\u20131166, 1181\u20131164)","journal-title":"Oncology (Williston Park)"},{"key":"2857_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s13577-012-0057-0","volume":"26","author":"N Yokomichi","year":"2013","unstructured":"Yokomichi N, Nagasawa T, Coler-Reilly A et al (2013) Pathogenesis of hand-foot syndrome induced by PEG-modified liposomal doxorubicin. Hum Cell 26:8\u201318. https:\/\/doi.org\/10.1007\/s13577-012-0057-0","journal-title":"Hum Cell"},{"key":"2857_CR20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ygyno.2004.05.027","volume":"94","author":"RD Drake","year":"2004","unstructured":"Drake RD, Lin WM, King M et al (2004) Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 94:320\u2013324. https:\/\/doi.org\/10.1016\/j.ygyno.2004.05.027","journal-title":"Gynecol Oncol"},{"key":"2857_CR21","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0190-9622(08)80126-0","volume":"24","author":"J Brown","year":"1991","unstructured":"Brown J, Burck K, Black D et al (1991) Treatment of cytarabine acral erythema with corticosteroids. J Am Acad Dermatol 24:1023\u20131025. https:\/\/doi.org\/10.1016\/S0190-9622(08)80126-0","journal-title":"J Am Acad Dermatol"},{"key":"2857_CR22","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/(SICI)1097-0142(19980301)82:5<965::AID-CNCR23>3.0.CO;2-Y","volume":"82","author":"PM Hoff","year":"1998","unstructured":"Hoff PM, Valero V, Ibrahim N et al (1998) Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 82:965\u2013969. https:\/\/doi.org\/10.1002\/(SICI)1097-0142(19980301)82:5%3c965::AID-CNCR23%3e3.0.CO;2-Y","journal-title":"Cancer"},{"key":"2857_CR23","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1046\/j.1365-2133.2002.04864.x","volume":"147","author":"R Van Doorn","year":"2002","unstructured":"Van Doorn R, Kirtschig G, Scheffer E et al (2002) Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 147:598\u2013601. https:\/\/doi.org\/10.1046\/j.1365-2133.2002.04864.x","journal-title":"Br J Dermatol"},{"key":"2857_CR24","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","volume":"144","author":"KJ Busam","year":"2001","unstructured":"Busam KJ, Capodieci P, Motzer R et al (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144:1169\u20131176. https:\/\/doi.org\/10.1046\/j.1365-2133.2001.04226.x","journal-title":"Br J Dermatol"},{"key":"2857_CR25","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1111\/j.1365-2133.2005.06885.x","volume":"153","author":"JC Pascual","year":"2005","unstructured":"Pascual JC, Belinch\u00f3n I, Sivera F et al (2005) Severe cutaneous toxicity following treatment with gefitinib (ZD1839). Br J Dermatol 153:1222\u20131223. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06885.x","journal-title":"Br J Dermatol"},{"key":"2857_CR26","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","volume":"28","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Mitchell EP, Piperdi B et al (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28:1351\u20131357. https:\/\/doi.org\/10.1200\/JCO.2008.21.7828","journal-title":"J Clin Oncol"},{"key":"2857_CR27","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2217\/fon.14.251","volume":"11","author":"Y Kobayashi","year":"2015","unstructured":"Kobayashi Y, Komatsu Y, Yuki S et al (2015) Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. Future Oncol 11:617\u2013627. https:\/\/doi.org\/10.2217\/fon.14.251","journal-title":"Future Oncol"},{"key":"2857_CR28","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1200\/JCO.23.01730","volume":"42","author":"A Santhosh","year":"2024","unstructured":"Santhosh A, Sharma A, Bakhshi S et al (2024) Topical diclofenac for prevention of capecitabine-associated hand-foot syndrome: a double-blind randomized controlled trial. J Clin Oncol 42:1821\u20131829. https:\/\/doi.org\/10.1200\/JCO.23.01730","journal-title":"J Clin Oncol"},{"key":"2857_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-022-02411-w","volume":"22","author":"Y Iimura","year":"2022","unstructured":"Iimura Y, Furukawa N, Ishibashi M et al (2022) Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study). BMC Gastroenterol 22:341. https:\/\/doi.org\/10.1186\/s12876-022-02411-w","journal-title":"BMC Gastroenterol"},{"key":"2857_CR30","doi-asserted-by":"publisher","first-page":"e1886","DOI":"10.1634\/theoncologist.2020-0698","volume":"25","author":"V Ostwal","year":"2020","unstructured":"Ostwal V, Kapoor A, Mandavkar S et al (2020) Effect of a structured teaching module including intensive prophylactic measures on reducing the incidence of capecitabine-induced hand-foot syndrome: results of a prospective randomized phase III study. Oncologist 25:e1886\u2013e1892. https:\/\/doi.org\/10.1634\/theoncologist.2020-0698","journal-title":"Oncologist"},{"key":"2857_CR31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s12664-020-01039-6","volume":"39","author":"K Watanabe","year":"2020","unstructured":"Watanabe K, Ishibe A, Watanabe J et al (2020) The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using capecitabine for colorectal cancer: the Yokohama Clinical Oncology Group Study (YCOG1102). Indian J Gastroenterol 39:204\u2013210","journal-title":"Indian J Gastroenterol"},{"key":"2857_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40268-016-0154-8","volume":"17","author":"LW Leicher","year":"2017","unstructured":"Leicher LW, de Graaf JC, Coers W et al (2017) Tolerability of capecitabine monotherapy in metastatic colorectal cancer: a real-world study. Drugs R D 17:117\u2013124. https:\/\/doi.org\/10.1007\/s40268-016-0154-8","journal-title":"Drugs R D"},{"key":"2857_CR33","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00280-017-3419-1","volume":"80","author":"K Danno","year":"2017","unstructured":"Danno K, Hata T, Tamai K et al (2017) Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer. Cancer Chemother Pharmacol 80:777\u2013785. https:\/\/doi.org\/10.1007\/s00280-017-3419-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"2857_CR34","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/S1470-2045(20)30527-1","volume":"21","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Meyerhardt J, Iveson T et al (2020) Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol 21:1620\u20131629. https:\/\/doi.org\/10.1016\/S1470-2045(20)30527-1","journal-title":"Lancet Oncol"},{"key":"2857_CR35","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2015.60.9107","volume":"33","author":"HJ Schmoll","year":"2015","unstructured":"Schmoll HJ, Tabernero J, Maroun J et al (2015) Capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol 33:3733\u20133740. https:\/\/doi.org\/10.1200\/JCO.2015.60.9107","journal-title":"J Clin Oncol"},{"key":"2857_CR36","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1200\/JCO.2017.76.0355","volume":"36","author":"T Andr\u00e9","year":"2018","unstructured":"Andr\u00e9 T, Vernerey D, Mineur L et al (2018) Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, International Duration Evaluation of Adjuvant (IDEA) France, phase III trial. J Clin Oncol 36:1469\u20131477. https:\/\/doi.org\/10.1200\/JCO.2017.76.0355","journal-title":"J Clin Oncol"},{"key":"2857_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.268","volume":"3","author":"J Harvey","year":"2023","unstructured":"Harvey J, Lax SJ, Lowe A et al (2023) The long-term safety of topical corticosteroids in atopic dermatitis: a systematic review. Skin Health Dis 3:e268. https:\/\/doi.org\/10.1002\/ski2.268","journal-title":"Skin Health Dis"},{"key":"2857_CR38","doi-asserted-by":"publisher","first-page":"237","DOI":"10.4103\/ijd.IJD_169_17","volume":"62","author":"A Das","year":"2017","unstructured":"Das A, Panda S (2017) Use of topical corticosteroids in dermatology: an evidence-based approach. Indian J Dermatol 62:237\u2013250. https:\/\/doi.org\/10.4103\/ijd.IJD_169_17","journal-title":"Indian J Dermatol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02857-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02857-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02857-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:04:10Z","timestamp":1761847450000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02857-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2857"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02857-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Narikazu Boku received lecture fees from Bristol Myers Squibb, Eli Lilly & Co., TAIHO PHARMACEUTICAL, CO., LTD., Astellas Pharma Inc.; Yohei Iimura, Keisuke Baba, Naoki Furukawa, Masaaki Ishibashi, Chieko Sasuga, Yuka Ahiko, Satoko Monma, Naoki Sakuyama, Susumu Aikou, Dai Shida3, Masanori Nojima, Seiichiro Kuroda, has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This protocol was reviewed and approved by the certified Clinical Research Review Board of the University of Tokyo (approval number: 2021512SP) prior to conducting the trial. This clinical trial was conducted in compliance with the Clinical Trials Act in Japan and was registered in the Japan Registry of Clinical Trials (jRCT) as jRCTs031220002.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients were required to provide written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}